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OBJECTIVES The goal of this study was to determine the therapeutic efficacy of angiotensin-converting
enzyme (ACE) inhibitors and beta-adrenergic receptor blockers in experimental chronic
mitral regurgitation (MR), gaining knowledge using methods difficult to apply in humans.
BACKGROUND Both ACE inhibitors and beta-blockers are cornerstones in the treatment of human
congestive heart failure. However, the roles of these treatments for chronic MR is unclear.
METHODS Mitral regurgitation was created in 11 closed-chest dogs. Three months after the creation, the
ACE inhibitor lisinopril 20 mg was given orally daily. After three months of lisinopril
therapy, the beta-blocker atenolol was added to lisinopril for another three months. Atenolol
was begun at a dose of 12.5 mg daily and increased gradually to 100 mg daily. Hemodynamics
and left ventricular (LV) function were assessed throughout the study.
RESULTS Regurgitant fraction was consistently50% over the course of this study. Pulmonary capillary
wedge pressure and LV end-diastolic pressure were significantly increased after three months
of MR and decreased during both lisinopril and the combined therapy in which it was not
different from baseline. Left ventricular contractility measured by the end-systolic stiffness
constant was depressed from 3.66  0.20 to 2.65  0.12 (p  0.05) at three months of MR
and rose insignificantly after lisinopril treatment (2.99  0.17). When atenolol was added, it
rose significantly and returned to normal (3.50  0.22, p  0.05).
CONCLUSIONS Although lisinopril significantly reduced preload, its effect on LV contractility was insignif-
icant in experimental MR. Conversely, atenolol, when added to lisinopril, achieved maximum
hemodynamic benefit and also restored LV contractility. (J Am Coll Cardiol 2002;40:
149–54) © 2002 by the American College of Cardiology Foundation
Angiotensin-converting enzyme (ACE) inhibitors have
been conclusively shown to improve long-term prognosis in
human heart failure trials (1,2). Although the exact mech-
anism of the beneficial effects of ACE inhibitors is still
unclear, it has become clear that ACE inhibitors improve
hemodynamics, block the production of angiotensin II and
increase bradykinin levels (3). Furthermore, ACE inhibitors
block maladaptive growth by mitogenic signaling (4–6).
However, the effects of ACE inhibitors in human mitral
regurgitation (MR) have been controversial and not well
studied. In some studies ACE inhibitors improved left
ventricular (LV) function with or without decreased regur-
gitation (7,8). In other studies, captopril depressed LV
performance possibly by a negative inotropic effect (9–11).
Therefore, the first goal of this study was to define the role
of ACE inhibitors in the treatment of chronic MR in a
canine model, where the consequences of the disease un-
treated with surgery could be ethically observed, while at the
same time enabling measurements of mechanics and con-
tractile function that are difficult to make in sick human
subjects.
Beta-adrenergic receptor blockers have caused striking
long-term improvement in LV function as well as in
mortality in human chronic heart failure (12,13). The
benefits of beta-adrenergic receptor blockers are probably a
class effect (14), and they reduce mortality in patients who
were already receiving ACE inhibitors (15,16). Although
the exact mechanisms by which beta-blockers improve
survival in heart failure patients are not yet established, we
found that beta-blockers ameliorate LV contractile dysfunc-
tion in experimental MR by restoring cellular contractile
elements (17), which is possibly established by energy-
sparing effects through slowing heart rate (18). Accordingly,
the second purpose of this study was to determine whether
there were additional benefits to the addition of beta-
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blockers to ACE inhibitors in chronic experimental MR
and to define specific mechanisms by which each drug
might be beneficial.
METHODS
Study design. As shown in Figure 1, 11 previously unre-
ported adult male mongrel dogs weighing 18.6 to 26.8 kg
were studied longitudinally from baseline when they were
normal through nine months of chronic MR. At three
months of MR, all animals were given lisinopril 20 mg
orally daily. After three months of ACE inhibition, beta-
blockade was gradually induced with atenolol at a starting
dose of 12.5 mg daily to a total of 100 mg daily as previously
described (17,18). The animals then were followed for
another three months. Because all dogs were followed
longitudinally from when they were normal, they served as
their own controls. At the nine-month study, the animals
were humanely euthanized under deep anesthesia. The
experimental protocol was approved by the Animal Subjects
Committee of the Medical University of South Carolina.
All the animals in this study received humane care in
compliance with the animal use principles of the American
Physiological Society and the Principles of Laboratory
Animal Care formulated by the National Society for Med-
ical Research and the Guidelines for the Care and Use of
Laboratory Animals prepared by the National Institutes of
Publication No. 85-23, revised 1984).
Catheterization. All studies were performed during light
anesthesia produced by the combination of fentanyl/
droperidol and inhaled nitrous oxide (nitrous oxide/oxygen
ratio of 3:1). This combination of anesthetic drugs has, been
shown previously to have a little effect on cardiac contractile
state (19). At the initial study, catheter access was estab-
lished over the right cervical vessels and over either right or
left femoral vessels at the subsequent studies. Two pigtail
catheters were introduced into the LV and the ascending
aorta via the carotid or the femoral artery and were con-
nected to mercury-calibrated water-filled transducers. A
Swan-Ganz catheter was advanced into the pulmonary
artery via the jugular or the femoral vein to obtain pulmo-
nary capillary wedge pressure (PCWP) and cardiac output
by the thermodilution method. A 25-mm balloon catheter
was advanced into the inferior vena cava through the same
vein to alter LV volume and pressure during ventriculogra-
phy by inflating and deflating the balloon. After baseline
measurements, a standard left ventriculogram using non-
ionic contrast (iohexol) was performed. After a 10-min
equilibration, a second ventriculogram was then taken and
timed to coincide with balloon deflation such that beat-by-
beat increases in both LV pressure and volume were
recorded simultaneously. These procedures were repeated at
each observation period shown in Figure 1. The pressure-
volume data produced from these alterations would be used
to construct the index of LV contractile function discussed
below.
Creation of MR. Mitral regurgitation was created by the
technique we have previously described (17–23). Briefly,
after baseline measurements were made in the initial study,
a urologic calculus retrieving forceps was advanced to the
mitral valve apparatus via a 7F sheath introduced into LV
retrograde through the right carotid artery and was used to
rupture chordae tendinae. When PCWP rose to 20 mm Hg
and forward stroke volume was reduced to 50% of its
baseline value, a ventriculogram was taken to confirm
angiographically that severe MR had been created and to
calculate regurgitant fraction to quantify the amount of MR.
Assessment of in vivo LV contractile function. In vivo
contractile function was assessed in this experiment using
the end-systolic stiffness constant derived from end-systolic
stress-(ESS)-strain relation analysis (21). Because strain is a
dimensionless property, this index is independent of LV
chamber size. It has correlated well with changes in con-
tractile function of isolated cardiac myocytes in our previous
studies in which sarcomere contractility served as an inde-
pendent standard of contractile function (17,18,20,23). At
all times, studies were made during acute beta-blockade
induced by the infusion of esmolol given intravenously with
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ANOVA  analysis of variance
BW  body weight
EDP  end-diastolic pressure
EDS  end-diastolic stress
ESS  end-systolic stress
MR  mitral regurgitation
LV  left ventricle/ventricular
PCWP  pulmonary capillary wedge pressure
RF  regurgitant fraction
Figure 1. Study protocol. MR  mitral regurgitation.
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a loading dose of 1.5 mg/kg/min followed by a constant
infusion of 300 g/kg/min. Acute beta-blockade was used
to prevent adrenergic reflexes from confounding measure-
ments of intrinsic contractility and provide consistency of
beta-adrenergic effects at four experimental observations
(23).
Calculations. Left ventricular volumes were determined by
the area-length method. This method has previously been
validated as providing an accurate measurement of LV
volume and mass in dogs with MR in studies in our
laboratory (19). The regurgitant fraction (RF) (%) was
calculated as: RF (%)  [(SVa  SVf) / Sva]  100, where
SVa is angiographically measured stroke volume (end-
diastolic volume  end-systolic volume) and SVf is forward
stroke volume (actual cardiac output measured by thermodi-
lution/heart rate). Wall stress was calculated by Mirsky’s
formula (24). The end-systolic stiffness constant (K-index)
was determined by fitting ESS and end-systolic wall thick-
ness data to the curvilinear equation as:   Celn(1/H),
where  is end-systolic wall stress, C is a constant,  is the
end-systolic stiffness constant and ln(1/H) is the natural
logarithm of the reciprocal of wall thickness. A detailed
discussion of mathematical derivation of this index was
previously described (21).
Statistics. All data are expressed as mean  1 SEM.
Comparisons made regarding given parameters over the
course of this study represented multiple repeated compar-
isons. Therefore, we used two-way analysis of variance
(ANOVA) to test statistical differences followed by a
Newman-Keuls test if ANOVA testing demonstrated that
significant differences were present. A value of p 0.05 was
considered statistically significant.
RESULTS
Figure 2 demonstrates that, although the combined therapy
of lisinopril and atenolol reduced RF slightly, RF did not
vary significantly over the course of this study and consis-
tently was 50%. As shown in Table 1, peak LV pressure
remained significantly lower than baseline after MR was
created as did end-systolic stress (ESS). Left ventricular
volume normalized for body weight (BW) significantly
Figure 2. Regurgitant fraction did not vary significantly over the course of this study and was consistently 50%. Lisinopril  angiotensin-converting
enzyme inhibitor; Atenolol  beta-adrenergic receptor blocker; MR  mitral regurgitation.
Table 1. Hemodynamic Parameters
Baseline
(No MR)
MR
(3 Months)
Lisinopril MR
(6 Months)
Lisinopril  Atenolol MR
(9 Months) ANOVA p
Heart rate (beat/min) 87  2 103  3* 86  3† 74  3*†‡ 0.0001
LV pressure peak (mm Hg) 122.8  3.5 98.3  4.0* 89.0  2.7* 95.2  2.4* 0.0001
EDP (mm Hg) 9.9  0.9 15.5  1.1* 11.0  0.9† 7.2  0.8*†‡ 0.0001
PCWP (mm Hg) 9.7  0.9 15.0  1.1* 11.1  1.2† 7.9  0.8*† 0.001
EDV/BW (ml/kg) 3.32  0.15 4.58  0.33* 4.62  0.47* 5.00  0.49* 0.0213
EF (%) 52.5  1.7 59.6  1.3* 60.8  2.1* 61.1  1.8* 0.003
ESS (kdyne/cm2) 177.1  12.1 127.0  5.2* 119.2  8.7* 125.1  5.9* 0.0001
EDS (kdyne/cm2) 25.0  2.4 39.9  3.8* 29.9  4.4† 30.3  4.8† 0.0205
Mean  SEM, *p  0.05 vs. baseline; †p  0.05 vs. MR (3 months); ‡p  0.05 vs. lisinopril by Newman-Keuls test.
ANOVA  analysis of variance; Atenolol  beta-adrenergic receptor blocker; EDP  end-diastolic pressure; EDS  end-diastolic stress; EDV/BW  ratio of end-diastolic
volume to body weight; EF  ejection fraction; ESS  end-systolic stress; LV  left ventricular; MR  mitral regurgitation; PCWP  pulmonary capillary wedge pressure.
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increased after creation of MR and remained consistently
elevated during the rest of the course of the study. Pulmo-
nary capillary wedge pressure and LV end-diastolic pressure
(EDP) were significantly increased at three months of MR.
They decreased significantly during lisinopril therapy when
they were not different from baseline (Table 1). Combined
therapy further reduced EDP compared with lisinopril
therapy alone. Along with these changes in PCWP and
EDP, LV EDS increased at three months of MR then
decreased significantly during lisinopril and the combined
therapy. However, it remained significantly greater than
baseline.
Figure 3 demonstrates LV mass normalized for body
weight. It increased significantly at three months of MR.
During lisinopril therapy, it decreased insignificantly, but it
was no longer significantly greater than baseline. It in-
creased again during the combined therapy and was signif-
icantly greater than baseline. Forward stroke volume deter-
mined by thermodilution was depressed at three months of
MR, as shown in Figure 4. It increased slightly but
insignificantly on lisinopril. During the combined therapy,
it rose significantly and returned to normal. Figure 5
demonstrates the change in end-systolic stiffness constant
(K-index), a load-independent contractility index. It was
depressed after three months of MR. It rose insignificantly
on lisinopril therapy. It rose further on the combined
Figure 3. Left ventricular mass normalized for body weight increased significantly after three months of MR. During lisinopril therapy, it decreased
insignificantly, but it was no longer greater than baseline. It increased again during the combined therapy and was significantly greater than baseline.
Abbreviations as in Figure 2. ANOVA  analysis of variance.
Figure 4. Forward stroke volume by thermodilution method was significantly depressed after three months of MR. Lisinopril increased it slightly. During
the combined therapy, it rose significantly and returned to normal. Abbreviations as in Figures 2 and 3.
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therapy and was significantly greater than untreated MR
and not different from baseline.
DISCUSSION
There were two major findings of this study. First, lisinopril
significantly reduced LV EDP, PCWP and EDS. However,
the effects of lisinopril on forward stroke volume and LV
contractility were insignificant. Left ventricular contractility
remained depressed on lisinopril therapy. Second, only
when a beta-blocker was added did forward stroke volume
and cardiac contractility return to normal. Addition of
atenolol to lisinopril further reduced EDP and PCWP.
Heart rate was significantly reduced after the addition of
atenolol among four measurements in this study. Left
ventricular mass decreased insignificantly on lisinopril ther-
apy and increased back insignificantly again during the
combination therapy.
ACE inhibitors and the MR heart. Our canine model of
pure severe volume overload significantly decreased ESS,
potentially accounting for a decline in LV wall thickness
(22). It also strikingly increased EDS and contributed to
eccentric hypertrophy and remodeling (25). Despite con-
tractile dysfunction, ejection fraction was preserved due to
favorable loading conditions. In the current study, ACE
inhibition reduced preload, but not afterload, possibly be-
cause afterload was already subnormal. On the other hand,
ACE inhibitors alone had no measurable effect on LV mass
or volume in this study, consistent with previous reports
(26). Consistent with heart failure studies in humans,
unloading achieved by ACE inhibition had no effect on LV
contractility. This contrasts with single-dose studies where
ACE inhibition had beneficial effects on LV function (7) or
negative inotropic effects (9).
Our study used indexes of contractility difficult to apply in
humans. These indexes, which found little change in con-
tractility with ACE inhibition help, confirm the concept
that ACE inhibition may produce its well-proven beneficial
effects in ways other than by directly enhancing myocardial
contractility.
Beta-blockers and the MR heart. While lisinopril failed
to improve LV contractile function in our MR model,
addition of the beta-blocker atenolol to lisinopril improved
the LV contractility substantially. Left ventricular contrac-
tility assessed by the end-systolic stiffness constant returned
to normal on combination therapy. This beneficial effect of
beta-blockade on LV contractile function in this study was
consistent with the findings in our previous reports in which
three months’ treatment of beta-blockers alone substantially
ameliorated the LV contractile dysfunction and improved
intrinsic contractility by restoration of contractile elements
in the cardiac myocytes isolated from MR hearts (17,18).
Myofibrillar density was significantly more associated with
the increased cross-sectional area of cardiac myocytes in the
beta-blocker treatment group than in untreated MR (17).
The beneficial findings of beta-blockers were associated
with significantly increased LV mass in the previous study
(17). A tendency towards increased LV mass occurred after
atenolol was added to lisinopril in this study.
Although precise mechanisms of the beneficial effects of
beta-blockers remain unclear, we suspect that beta-blockers
permitted the increase in the LV mass associated with an
increase in the number of contractile elements by allowing
load-induced cardiac hypertrophy again to occur under
protection from cathecholamine toxicity (17). As previously
reported (18), the beneficial effects of beta-blockers on
cellular and ventricular contractile function were associated
with a reduction in heart rate. Bradycardia might lead to: 1)
decreased oxygen consumption (27); 2) improved calcium
Figure 5. End-systolic stiffness constant (K-index) was significantly depressed after three months of MR. It rose insignificantly on lisinopril therapy. Only
when atenolol was added did contractility return to normal. Abbreviations as in Figures 2 and 3.
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handling, which could reduce calcium overload causing
myocardial injury; 3) improved myocardial metabolism by
restoring high energy phosphate (28); and 4) by moving the
ventricle to the point where contractility is maximum on its
force-frequency relationship (29). Angiotensin-Converting
enzyme inhibition reduced heart rate, but beta-blockade
reduced heart rate still further in this study. This difference
might be an explanation as to the different effects of the two
drugs on LV contractility in MR.
Study limitations. Data obtained in this study are limited
to an experimental model of MR, and applicability to
humans is uncertain.
This report is lacking a nine-month control group of
pharmacologically untreated chronic MR. However, the
changes after lisinopril and then after the combination
therapy would not be part of the natural history of chronic
MR because our untreated chronic MR model was charac-
terized as follows (17,18): 1) RF was unchanged over the
course of MR; 2) LV EDV continuously increased after MR
creation; 3) LV mass/BW increased by up to 45% at three
months and plateaued after six months; and 4) K-index was
severely depressed at three months, and this depression
persisted for the next three months. These previous findings
support that the chronic MR hearts in our model have
consistent LV dysfunction with continuous LV dilation
after three months of MR.
Conclusions. We conclude that ACE inhibition has ben-
eficial effects on filling pressure in experimental MR. How-
ever, only when beta-blockade was added was there a
substantial improvement in LV contractility and forward
stroke volume.
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